Xue Ge, Jack E Henningfield, Suresh Siddhanti, Janet Jobes, Lin Lu, Sunny Xie, Margaret Ziola, Debra Kelsh, Bradley Vince, Carlo J Di Fonzo, Mary Tagliaferri, Jonathan Zalevsky, Stephen K Doberstein, Ute Hoch, Michael A Eldon
OBJECTIVE: To evaluate the human abuse potential, pharmacokinetics, pharmacodynamics, and safety of oral NKTR-181 (oxycodegol), a novel full mu-opioid receptor agonist, relative to oral oxycodone. DESIGN: This double-blind, randomized, single-dose, crossover human abuse potential study was conducted in healthy, adult, non-physically dependent recreational opioid users. SETTING: Inpatient clinical research site. SUBJECTS: Seventy-one subjects randomized (95...
September 25, 2019: Pain Medicine